Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
PTC will acquire controversial DMD drug
by Michael McCoy
March 20, 2017
| A version of this story appeared in
Volume 95, Issue 12
PTC Therapeutics has agreed to acquire the Duchenne muscular dystrophy (DMD) treatment Emflaza from Marathon Pharmaceuticals for $140 million plus potential milestone payments. Marathon won FDA approval for Emflaza on Feb. 9 and immediately stirred controversy by pricing it at $89,000 per year, even though it is based on the generic steroid deflazacort. The firm subsequently paused the launch. PTC, which already markets the DMD treatment ataluren in Europe, says it is finalizing commercialization plans.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter